Eli Lilly and Company and Boehringer Ingelheim will collaborate on a phase Ib study that will evaluate the safety and tolerability of Lilly’s abemaciclib in combination with Boehringer Ingelheim’s BI 836845, in patients with HR+, HER2- metastatic breast cancer. According to the companies, the collaboration has the potential to expand to phase II trials in...
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).
